Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD3 | Q15059 | 2/20 | 0.45 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | TDO2 | P48775 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | BCDIN3D | Q7Z5W3 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.39 |
| ▸ | CDK9 | P50750 | 1/20 | 0.39 |
| ▸ | BUB1 | O43683 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12225226 | 0.82 | MEN1 (0.36) | IDO1TDO2KDM4EJAK1 | |
| SCHEMBL12205348 | 0.82 | JAK1 (0.44) | PRMT5IDO1TDO2GPR119SYK | |
| SCHEMBL12205234 | 0.80 | EHMT2 (0.36) | BRD3CCNT1CDK9BRD4 | |
| SCHEMBL12205335 | 0.79 | KDM4E (0.55) | IDO1TDO2GPR119SYKBCDIN3D | |
| SCHEMBL12132010 | 0.79 | BRD3 (0.41) | BRD3GPR119KDM4EJAK1 | |
| SCHEMBL12132079 | 0.78 | BTK (0.41) | BRD3GPR119KDM4EJAK1 | |
| SCHEMBL12247504 | 0.77 | KDM4E (0.51) | IDO1TDO2GPR119SYKBCDIN3D | |
| SCHEMBL12284988 | 0.76 | BRD3 (0.42) | BRD3KDM4EJAK1 | |
| SCHEMBL12127798 | 0.76 | DDB1 (0.37) | BRD3GPR119KDM4EJAK1 | |
| SCHEMBL12127873 | 0.75 | DDB1 (0.37) | BRD3GPR119KDM4EJAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110256064-A1 | Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-like Proteins | AC IMMUNE, S.A. (CH) | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110256064-A1 | Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-like Proteins | APP, PSEN1, PSEN2 | BRD3 2053/4885PRMT5 3112/4885IDO1 3990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.